ITEM VIEW

High-dose immunoglobulin therapy in four patients with onyalai

dc.contributor.authorHesseling P.B.
dc.date.accessioned2011-05-15T16:18:14Z
dc.date.available2011-05-15T16:18:14Z
dc.date.issued1991
dc.identifier.citationTransactions of the Royal Society of Tropical Medicine and Hygiene
dc.identifier.citation85
dc.identifier.citation1
dc.identifier.issn00359203
dc.identifier.other10.1016/0035-9203(91)90186-3
dc.identifier.urihttp://hdl.handle.net/10019.1/14569
dc.description.abstractOnyalai, a form of immune thrombocytopenia in Africa, has a recorded death rate of 9.8% in the acute phase due to haemorrhagic shock or central nervous system bleeding. Four patients with active bleeding and a mean platelet count of 6 x 109/litre were each treated with 0.67 g/kg intravenous globulin (Sandoglobulin®) daily on 3 successive days. Clinical bleeding ceased within 3 d and all patients responded with a rise in the platelet count, which peaked at 19-21 d. No side effect was recorded. Intravenous globulin therapy may reduce the morbidity of the acute phase of onyalai.
dc.subjectimmunoglobulin
dc.subjectimmunoglobulin g
dc.subjectadolescent
dc.subjectadult
dc.subjectarticle
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman experiment
dc.subjectintravenous drug administration
dc.subjectmale
dc.subjectpriority journal
dc.subjectthrombocytopenia
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectCase Report
dc.subjectChild
dc.subjectFemale
dc.subjectHuman
dc.subjectImmunization, Passive
dc.subjectImmunoglobulin G
dc.subjectImmunoglobulins, Intravenous
dc.subjectInfusions, Intravenous
dc.subjectMale
dc.subjectPlatelet Count
dc.subjectPurpura, Thrombocytopenic
dc.titleHigh-dose immunoglobulin therapy in four patients with onyalai
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW